Abstract: International audience ; The isolation of Circulating Tumor Cells (CTCs) directly from blood by liquid biopsy could lead to a paradigm shift in clinical cancer care by enabling earlier diagnosis, more accurate prognosis and personalized treatment. Nevertheless, the specific challenges of CTCs, including their rarity and heterogeneity, have so far limited the use of CTCs in clinical studies. Currently, no device fully meets the requirements of high recovery, high purity, short processing time and ease of use for end-users. A promising new strategy involves combining a higher throughput but less specific pre-enrichment step based on size sorting together with a highly specific but slower immunomagnetic sorting. This approach requires the initial function to operate at lower flow rates than commonly used to connect the two functions in series. In this context, we developed a Dean spiral microfluidic device, optimized for sorting 10µm and 15µm beads by size. We showed that it successfully separates mimicking CTCs from white blood cells at low flow rates (<100 mL/h). a
Processing Request
No Comments.